Bert O'Neil
Indiana University Bloomington
H-index: 57
North America-United States
Top articles of Bert O'Neil
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Somatostatin analogs and hepatocellular carcinoma | cancer Biology & therapy | Laura Raftery Bert H O’Neil | 2040 |
Abstract PO3-20-04: A first-in-human study of the highly selective PI3Kα inhibitor RLY-5836 in patients with advanced breast cancer and other solid tumors | Cancer Research | Andreas Varkaris Steven Isakoff Cesar A Perez Bert O'Neil Erika Hamilton | 2024/5/2 |
A Meta-Analysis of Efficacy and Safety Data from Head-to-Head First-Line Trials of Epidermal Growth Factor Receptor Inhibitors versus Bevacizumab in Adult Patients with RAS … | Takayuki Yoshino Naushin Hooda Diana Younan Kei Muro Kohei Shitara | 2024/3/1 | |
A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma | The Oncologist | Shawn Yu Menggang Yu Barry Keane David M Mauro Paul R Helft | 2024/2/7 |
127P A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination … | Annals of Oncology | T Yoshino N Hooda D Younan K Muro K Shitara | 2023/11/1 |
Pembrolizumab for previously treated, microsatellite instability–high/mismatch repair–deficient advanced colorectal cancer: final analysis of KEYNOTE-164 | European Journal of Cancer | Dung T Le Luis A Diaz Jr Tae Won Kim Eric Van Cutsem Ravit Geva | 2023/6/1 |
660MO First-in-human study of SGN-B7H4V, a B7-H4-directed vedotin ADC, in patients with advanced solid tumors: Preliminary results of a phase I study (SGNB7H4V-001) | Annals of Oncology | CA Perez JT Henry N Lakhani JA Call EP Hamilton | 2023/10/1 |
A study of pembrolizumab (pembro) in combination with Y90 radioembolization in patients (pts) with poor prognosis hepatocellular carcinoma (HCC). | Ashwin Somasundaram Paul R Helft William Proctor Harris Hanna Kelly Sanoff Guy E Johnson | 2023/2/1 | |
Zanzalintinib in combination with immune checkpoint inhibitors: Design of the renal cell carcinoma expansion stage cohorts in STELLAR-002 | The Oncologist | Robert J Motzer Toni K Choueiri Benjamin Garmezy Bert O’Neil Joel Michalski | 2023/9/1 |
Abstract PR006: Initial results from first-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in biomarker-selected solid tumors | NaN | Jordi Rodon Noboru Yamamoto Toshihiko Doi François Ghiringhelli Maria-Elisabeth Goebeler | 2023 |
Phase II randomised, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN GI14-198) | European Journal of Cancer | Walid L Shaib Rupji Manali Yuan Liu Bassel El-Rayes Patrick Loehrer | 2023/8/1 |
Common variation in a long non-coding RNA gene modulates variation of circulating TGF-β2 levels in metastatic colorectal cancer patients (Alliance) | medRxiv | Julia CF Quintanilha Alexander B Sibley Yingmiao Liu Donna Niedzwiecki Susan Halabi | 2023/12/4 |
Subcutaneous amivantamab (ami) in patients (pts) with advanced solid malignancies: The PALOMA study—Updated safety and identification of the recommended phase 2 dose. | Anna Rachel Minchom Matthew G Krebs Byoung Chul Cho Se-Hoon Lee Natasha B Leighl | 2023/6/1 | |
1198TiP A phase Ib/II open-label, nonrandomized study of FGFR inhibitor futibatinib in combination with MEK inhibitor binimetinib in patients with advanced KRAS-mutant cancer | Annals of Oncology | J Rodon B O’Neil V Wacheck M Liu LS Rosen | 2022/9/1 |
Abstract PD9-10: BRE12-158: A post-neoadjuvant, randomized phase 2 trial of personalized therapy vs. treatment of physician’s choice for patients with residual triple negative … | Cancer Research | Bryan P Schneider Guanglong Jiang Tarah J Ballinger Fei Shen Christopher Chitambar | 2022/2/15 |
Use of clinical RNA-sequencing in the detection of actionable fusions compared to DNA-sequencing alone. | Jackson Michuda Ben Ho Park Amy Lauren Cummings Siddhartha Devarakonda Bert O'Neil | 2022/6/1 | |
EP08. 02-116 Design of a Phase 1 Study of AMG 193, an MTA-Cooperative PRMT5 Inhibitor, in Patients with Advanced MTAP-Null Solid Tumors | Journal of Thoracic Oncology | M Villalona Calero A Patnaik R Maki B O'Neil J Abbruzzese | 2022/9/1 |
BRE12-158: A postneoadjuvant, randomized phase II trial of personalized therapy versus treatment of physician's choice for patients with residual triple-negative breast cancer | Journal of clinical oncology | Bryan P Schneider Guanglong Jiang Tarah J Ballinger Fei Shen Christopher Chitambar | 2022/2/1 |
Design and rationale of a phase 1 dose-escalation study of AMG 193, a methylthioadenosine (MTA)-cooperative PRMT5 inhibitor, in patients with advanced methylthioadenosine … | Miguel Angel Villalona-Calero Amita Patnaik Robert G Maki Bert O'Neil James L Abbruzzese | 2022/6/1 | |
Plasma protein biomarkers in advanced or metastatic colorectal cancer patients receiving chemotherapy with bevacizumab or cetuximab: results from CALGB 80405 (Alliance) | Clinical Cancer Research | Andrew B Nixon Alexander B Sibley Yingmiao Liu Ace J Hatch Chen Jiang | 2022/7/1 |
